Publications by authors named "Emilio Usala"

Claim this Profile
H
Health-related quality of life profile of patients with immune thrombocytopenia in the real life is impaired by splenectomy.
Giovanni Caocci, Fabio Efficace, Olga Mulas, Francesco Cottone, Alessia Maxia, Emilio Usala

Ann Hematol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia.
Diletta Fontana, Daniele Ramazzotti, Andrea Aroldi, Sara Redaelli, Vera Magistroni, Emilio Usala

Hemasphere· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting.
Giovanni Caocci, Maria Pina Simula, Silvia Ghiani, Olga Mulas, Giorgia Mainas, Emilio Usala

Int J Hematol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flow Cytometry Assessment of CD26 Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia.
Donatella Raspadori, Paola Pacelli, Anna Sicuranza, Elisabetta Abruzzese, Alessandra Iurlo, Emilio Usala

Cytometry B Clin Cytom· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.
Giovanni Caocci, Olga Mulas, Mario Annunziata, Luigiana Luciano, Massimiliano Bonifacio, Emilio Usala

Am J Hematol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.
Rocco Piazza, Vera Magistroni, Sara Redaelli, Mario Mauri, Luca Massimino, Emilio Usala

Nat Commun· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Residual Peripheral Blood CD26 Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.
Monica Bocchia, Anna Sicuranza, Elisabetta Abruzzese, Alessandra Iurlo, Santina Sirianni, Emilio Usala

Front Oncol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Fausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, Alessandra Iurlo, Luciano Levato, Emilio Usala

Am J Hematol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.
Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, Antonella Gozzini, Emilio Usala

Am J Hematol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.
Massimo Breccia, Fabio Efficace, Simona Sica, Elisabetta Abruzzese, Michele Cedrone, Emilio Usala

Leuk Res· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.
Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, Luciano Levato, Mariella D'Adda, Emilio Usala

Haematologica· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reproducibility of liver iron concentration measured on a biopsy sample: a validation study in vivo.
Silvana Anna Maria Urru, Igor Tandurella, Mario Capasso, Emilio Usala, Donatella Baronciani

Am J Hematol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia.
Carlo B Gambacorti-Passerini, Carla Donadoni, Andrea Parmiani, Alessandra Pirola, Sara Redaelli, Emilio Usala

Blood· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.
Luigi Gugliotta, Alessia Tieghi, Giovanni Tortorella, Potito Rosario Scalzulli, Rosanna Ciancia, Emilio Usala

Leuk Res· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
Paola Guglielmelli, Giovanni Barosi, Alessandro Rambaldi, Roberto Marchioli, Arianna Masciulli, Emilio Usala

Blood· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells.
Adriana Borriello, Ilaria Caldarelli, Debora Bencivenga, Valeria Cucciolla, Adriana Oliva, Emilio Usala

Carcinogenesis· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.
Giuseppe Visani, Massimo Breccia, Antonella Gozzini, Giorgina Specchia, Enrico Montefusco, Emilio Usala

Am J Hematol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.
Francesco Zaja, Michele Baccarani, Patrizio Mazza, Monica Bocchia, Luigi Gugliotta, Emilio Usala

Blood· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry.
Lorella Melillo, Alessia Tieghi, Anna Candoni, Franca Radaelli, Rosanna Ciancia, Emilio Usala

Am J Hematol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis